Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PL8177 subcutaneous injection in healthy volunteers for inflammatory blister response
2019-003197-24Phase 2Terminated
- Sponsor
- Palatin Technologies, Inc.
- Start
- Jan 2020
- Modality
- Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of PL8177 (3 arms), sponsored by Palatin Technologies, Inc. Primary endpoint: Difference in blister fluid volume compared with placebo. Started Jan 2020; status: terminated.
02
Drugs
PL8177
Beyond the preview
Go deeper on 2019-003197-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003197-24.